期刊文献+

Liquid biopsies in pancreatic cancer:targeting the portal vein

原文传递
导出
摘要 Pancreatic cancer is a highly lethal malignancy with poor overall survival due to silent progression until primary tumor growth or metastatic dissemination develops clinical symptoms.Even in the minority of patients with early diagnosis and candidacy for curative intent surgery,postoperative recurrence after surgical resection is very frequent.Due to these findings,efforts to identify minimally invasive ways to provide earlier diagnosis and enhanced prognostication are increasingly warranted.Liquid biopsies assessing for tumor derived materials shed into the blood are a promising tool to accomplish this goal;however,in pancreatic cancer,peripheral blood analyses remain dependent on the degree of tumor burden with a prohibitively low yield until the cancer is widely metastatic.To overcome this limitation,increasing literature has emerged evaluating the possibility of portal venous blood as a new,potentially higher yield liquid biopsy target in pancreatic cancer.This review will discuss the current literature and clinical application potential of mesenteric vasculature,or portal venous blood,as liquid biopsies in the diagnosis,prognosis and management of patients with pancreatic cancer.
出处 《Journal of Pancreatology》 2019年第3期76-81,共6页 胰腺病学杂志(英文)
  • 相关文献

参考文献1

二级参考文献14

  • 1Katz MH, Wang H, Fleming JB, et al.Long-term survival after muhidisciplinary management of resected pancreatic adenocar- cinoma [ J ].Ann Surg Oncol, 2009,16(4) : 836-847.
  • 2Khorana AA, Mangu PB, Berlin J, et al. Potentially Curable Pan- creatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline [ J ]. J Clin Oncol, 2016,34 (21 ) : 2541-2556.
  • 3Balaban EP, Mangu PB, Khorana AA, et al. Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline [J]. J Clin Oncol, 2016, 34 (22) : 2654-2668.
  • 4Sohal DP, Mangu PB, Khorana AA, et al. Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline [J ]. J Clin Oncol, 2016,34 (23) : 2784-2796.
  • 5Yamada S, Fujii T, Sugimoto H, et al. Aggressive surgery for bor- derline resectable pancreatic cancer: evaluation of National Comprehensive Cancer Network guidelines [ J ] Pancreas, 2013, 42(6): 1004-1010.
  • 6National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology.Pancreatic Adenocarcinoma.Version 1.2016. [S/OL]. [2016-08-29].Available from: http://www.nccn. org/ professionals/ physician gls/f_guidelines.asp.
  • 7Dale W, Hemmerich J, Kamm A, et al. Geriatric assessment im- proves prediction of surgical outcomes in older adults undergo- ing pancreaticoduodenectomy: A prospective cohort study [J]. Ann Surg, 2014,259(5): 960-965.
  • 8Marrelli D, Caruso S, Pedrazzani C, et al. CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions [J]. Am J Surg, 2009,198(3): 333-339.
  • 9Valle JW, Palmer D, Jackson R, et al. Optimal duration and timing of adjuvant chemotherapy after definitive surgery for ductal adenocarcinoma of the pancreas: ongoing lessons from the ESPAC-3 study [J ]. J Clin Oncol, 2014,32(6) : 504-512.
  • 10Neoptolemos JP, Stocken DD, Friess H, et al. A randomized tri- al of chemoradiotherapy and chemotherapy after resection of pancreatic cancer [J]. N Engl J Med, 2004, 350(12): 1200-1210.

共引文献11

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部